IMEXPHARM CORPORATION

Imexpharm (IMP) is one of the leading enterprises in the field of pharmaceutical production and distribution with a diverse product portfolio that satisfies the treatment needs of both OTC (pharmacies) and ETC (hospitals, clinics channels). Imexpharm's strength is new generation antibiotic lines, produced on a modern production line system meeting advanced standards (EU-GMP). Currently, IMP has 4 factory clusters, operating a total of 7 factories and workshops. In 2023, factories IMP2 and IMP3 received EU-GMP certification for the 2nd and 3rd consecutive times, respectively. IMP1 factory cluster contributes the largest revenue of 50%, IMP3 factory cluster contributes 32%. IMP4 Factory meets EU-GMP standards and recorded sales of VND 80 billion after 5 months of operation in 2023. The company owns the largest number of production lines meeting EU-GMP standards in Vietnam, bringing a strong competitive advantage in the hospital channel. Its shares were listed on HOSE with the code IMP on November 15, 2006.

In 2023, IMP registered 11 more registration numbers for 6 products in Europe, including complex products such as Ampicillin/Sulbactam; increasing the total to 27 marketing licenses in Europe for 11 product types. According to Ms. Tran Thi Dao, the company will continue to maximize the number of registrations in the European chain, expanding the ETC customer file from 600 to 1,000 customers in the next 5 years. At the same time, expand the list of raw material suppliers and develop competitive pricing strategies to increase ETC market share.

The subject announced the Board of Directors Resolution on implementing dividend payments in 2023. Accordingly, IMP will pay a total dividend rate of 20%, including 10% in cash (corresponding to spending of more than VND 70 billion) and 10% in stocks.
Regarding stock dividends, the subject plans to issue more than 7 million shares (corresponding to 10% of the number of outstanding shares) to pay dividends to shareholders at a rate of 10%, i.e. shareholders who own 10 shares will receive 1 new share. After this share issuance to pay dividends, Imexpharm's charter capital will increase to VND 770 billion.
IMP will also continue to expand specialty drug groups, diversifying the product portfolio including manufacturing and distributing drugs to treat cardiovascular, diabetes, respiratory, neurological and eye diseases, vitamins and minerals. The vitamin and functional food segment is in line with the strongly growing demand of the health care product market. Therefore, the company has also invested in a specialized factory to produce these products.